Goldenwell Biotech Faces Financial Struggles Despite Stable Inventory and Cost Control Efforts

### Goldenwell Biotech, Inc. (PINK: GWLL) - Recent Developments

Company Overview: Goldenwell Biotech, Inc. is in the development stage focusing on R&D, production, and sales of health care and supplements products. As of the quarterly report ending March 31, 2025, the company has not yet generated any revenues.

Positive Aspects:

• Operating expenses saw only a moderate increase from $28,956 in Q1 2024 to $32,277 in Q1 2025, indicating some cost control.
• The company maintains a consistent issued common stock of 99 million shares, which provides a stable base for potential equity financing.
• Inventory is stable at $174,788, which indicates preparedness for future sales once production begins.

Negative Aspects:

• Revenue remains at $0 for both Q1 2025 and Q1 2024, demonstrating ongoing challenges in executing their business plan.
• Net losses increased from $31,056 in Q1 2024 to $34,377 in Q1 2025, exacerbating the accumulated deficit which now totals $1,394,022.
• The cash balance significantly declined from $49,404 to $17,127, indicating liquidity issues.
• Total liabilities have risen to $273,533, exceeding total assets of $191,915, leading to a stockholders' equity deficit of $(81,618).

Key Statistics:

• Common Stock Issued: 99,000,000 shares
• Total Assets: $191,915
• Cash & Cash Equivalents: $17,127
• Total Liabilities: $273,533
• Net Loss: $(34,377)
• Accumulated Deficit: $(1,394,022)

Goldenwell Biotech continues to face significant hurdles as it seeks to begin operations amidst a challenging financial landscape. Their path forward hinges on successful capital raising efforts and the eventual generation of revenue through product sales.